Researchers leading the SWOG S1712 clinical trial have found that adding ruxolitinib to standard tyrosine kinase inhibitor ...

Researchers leading the SWOG S1712 clinical trial have found that adding ruxolitinib to standard tyrosine kinase inhibitor ...

Treatment of chronic myeloid leukemia (CML) has changed drastically with the emergence of the Abl tyrosine kinase inhibitor (TKI), imatinib mesylate. However, primary and secondary resistance have ...

Researchers leading the SWOG S1712 clinical trial have found that adding ruxolitinib to standard tyrosine kinase inhibitor ...

Erlotinib is a quinazoline derivative that selectively and reversibly inhibits the tyrosine kinase activity of the EGFR. Here, we review the mechanism(s) of action of erlotinib, as well as the ...

Study explores the potential to repurpose neuroactive drugs, originally approved for neurological disorders, for the ...

In a report released yesterday, Sam Slutsky from LifeSci Capital maintained a Buy rating on Ventyx Biosciences (VTYX – Research Report).

Nuvalent's promising lead candidates and strong investor interest has put the stock under the spotlight. Read more about the ...

Careful management by a team of specialists is needed to balance disease control and fetal health in patients with CML who are pregnant or trying to become prengant.

The specter of elevated liver enzymes, a known problem with the drug class, became a topic of talk with regard to Sanofi SA’s ...

Tolebrutinib belongs to a class of drugs that target microglia through an enzymatic target called BTK (Bruton Tyrosine Kinase). Masitinib also targets microglia but through a different enzymatic ...